Skip to main content

Sorilux FDA Approval History

FDA Approved: Yes (First approved October 7, 2010)
Brand name: Sorilux
Generic name: calcipotriene
Dosage form: Foam
Company: Mayne Pharma US
Treatment for: Psoriasis

Sorilux (calcipotriene) is a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years and older.

Development timeline for Sorilux

May 22, 2019Approval FDA Approves Sorilux for Adolescent Plaque Psoriasis
Oct 12, 2010Approval Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.